Hamlet BioPharma AB (publ)
Research Hamlet BioPharma AB (publ) (HAMLET-B.ST) on Bullrun: market cap SEK 1.11B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerHAMLET-B.ST
- ExchangeXSAT
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencySEK
- Market capSEK 1.11B
- Financial periodQ2 2026
- RevenueSEK 0
- Net income-SEK 15.86M
- Free cash flow-SEK 8.94M
Valuation Snapshot
latest market cap is SEK 1.11B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | SEK 1.11B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 SEK.
About Hamlet BioPharma AB (publ)
Hamlet BioPharma AB (publ) engages in the development of drugs for the treatment and prevention of cancer in Sweden. It is developing HAMLET, a tumoricidal protein-lipid complex formed by two generally regarded as safe (GRAS) molecules found in human milk for various oncology markets, including colon, bladder, and cervix cancers, as well as primary or metastatic brain tumors. The company's products under development include Alpha1H for the treatment of bladder cancer and brain tumors;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Hamlet BioPharma AB (publ)'s market cap?
Hamlet BioPharma AB (publ)'s market capitalization is SEK 1.11B.
What does Hamlet BioPharma AB (publ) do?
Hamlet BioPharma AB (publ) engages in the development of drugs for the treatment and prevention of cancer in Sweden. It is developing HAMLET, a tumoricidal protein-lipid complex formed by two generally regarded as safe (GRAS) molecules found in human milk for various oncology markets, including colon, bladder, and cervix cancers, as well as primary or metastatic brain tumors. The company's products under development include Alpha1H for the treatment of bladder cancer and brain tumors; and BAMLET for the treatment of colon and oral cancer.